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Expression of non-rearranged HLA class I-binding receptors characterizes human and
mouse NK cells. The postulation of the missing-self hypothesis some 30 years ago trig-
gered the subsequent search and discovery of inhibitory MHC-receptors, both in humans
and mice. These receptors have two functions: (i) to control the threshold for NK cell acti-
vation, a process termed “licensing” or “education,” and (ii) to inhibit NK cell activation
during interactions with healthy HLA class I-expressing cells. The discovery of activating
forms of KIRs (aKIR) challenged the concept of NK cell tolerance in steady state, as well
as during immune challenge: what is the biological role of the activating KIR, in particular
when NK cells express aKIRs in the absence of inhibitory receptors? Recently it was shown
that aKIRs also participate in the education of NK cells. However, instead of lowering the
threshold of activation like iKIRs, the expression of aKIRs has the opposite effect, i.e., ren-
dering NK cells hyporesponsive. These findings may have consequences during NK cell
response to viral infection, in cancer development, and in the initial stages of pregnancy.
Here we review the current knowledge of activating KIRs, including the biological concept
of aKIR-dependent NK cell education, and their impact in health and disease.
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INTRODUCTION
The history of non-rearranged MHC class I-binding receptors has
been a passionate story for three decades. Shortly after the discov-
ery of NK cells in the mid-1970s (1, 2) MHC class I was suspected
to be important for regulating NK cell responses (3–5). The sub-
sequent postulation of the “missing-self” hypothesis (1, 2, 6), pre-
dicted that NK cells would express inhibitory MHC class I-binding
receptors. In 1992, the discovery of inhibitory MHC class I-binding
Ly49 receptors in mice transformed the “missing-self” hypothesis
into a now well-admitted dogma (3–5, 7). Shortly after, human
inhibitory receptors binding to HLA-C (KIR2DL1/P58.1/EB6 and
KIR2DL3/P58.2/GL183) (8–10) and HLA-B (NKB1/KIR3DL1)
(11), were identified as functional analogs to the murine inhibitory
Ly49 receptors. Moretta and Colleagues later discovered that the
monoclonal antibody clone EB6 also could recognize a second
receptor p50 (KIR2DS1), and that this receptor transmitted acti-
vating signals upon recognition of HLA-Cw4 targets (12). The
genes coding for these receptors were later cloned and were con-
firmed to be specific for HLA-B and -C molecules (13). Since
the initial discovery of the first inhibitory and activating KIRs in
humans (referred to iKIRs and aKIRs respectively in the rest of
the manuscript), a number of additional KIRs have been iden-
tified. The KIR family now includes seven iKIR and six aKIR,
in addition to KIR2DL4, which has both inhibitory and acti-
vating function. Adding to the complexity, each KIR gene is
highly polymorphic, and the product of different alleles can
interact more or less strongly with different HLA class I alleles
(Table 1).
All KIR genes are encoded in the leukocyte receptor complex
(LRC) in the chromosome 19 (19q14.3). Thus, the LRC includes
the 15 genes of the KIR family. Importantly, for some KIRs, there
is extreme allele variability, whereas some KIR genes are highly
conserved and exist only as few alleles. The variability of KIR
alleles can be nicely visualized1. Interestingly, compared to iKIR,
aKIR display rather limited allele variability compared to iKIR.
For instance there are more than 75 alleles coding for KIR3DL1
and only 17 coding for KIR3DS1 (32), and KIR2DS1 gene encom-
passed only 16 alleles in contrast to KIR2DL1 gene, which include
more than 40 alleles2.
In addition to allele polymorphism, there is strong haplotype
variability due to the number of KIR genes present in the LRC.
Two types of KIR haplotypes, A and B, have been defined pending
on gene content. Group B haplotypes are defined by the presence
of at least one of the following KIR genes: KIR2DL5, KIR2DS1,
KIR2DS2, KIR2DS3, KIR2DS5, and KIR3DS1. Conversely, group
A haplotypes are characterized by the absence of all these genes. All
information about KIR alleles and haplotypes has been collected
in the KIR web-based database (see text footnote 1). In addition,
another repository has been created for association between KIR
and diseases3 (33).
Currently, the aKIR include KIR2DS1, KIR2DS2, KIR2DS3,
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Table 1 | Activating and inhibitory KIRs and ligands.
Activating KIR Ligand Detectable by FACS Reference
2DS1 HLA-C2 (weaker than 2DL1) Yes (14, 15)
2DS2 HLA-C1 (weak), HLA-A*11:01 Yes (16–18)
2DS3 Unknown ? (Retained intracellularly?) (19)
2DS4 HLA-C*05:01, A*11:02, C*16:01 Yes (20)
2DS5 Unknown Yes (21–23)
3DS1 Unknown Yes (24)
Inhibitory KIR Ligand Detectable by FACS
2DL1 HLA-C2 (N77/K80) Yes (8)
2DL2 HLA-C1 (S77/N80), HLA-C2, HLA-B*46:01 and HLA-B*73:01 (C1 epitope) Yes (9, 25)
2DL3 HLA-C1 (S77/N80), HLA-C2, HLA-B*46:01 and HLA-B*73:01 (C1 epitope) Yes (9, 25)
2DL4 HLA-G (intracellular interaction?) Yes (not shown in vivo) (26)
2DL5A/B Unknown Yes (27)
3DL1 HLA-A (with Bw4 motif), HLA-Bw4 Yes (11, 28)
3DL2 HLA-A3/A11 Yes (29, 30)
3DL3 Unknown ? (Methylated promoter) (31)
each receptor as well as their cell surface expression has been elu-
sive for many years, despite the fact that the extracellular domains
of these molecules are extremely similar to their inhibitory coun-
terparts, in terms of sequence and 3D structure. Studies impli-
cating aKIRs in diseases are therefore almost exclusively based on
genetic studies. More recently, new staining protocols and mon-
oclonal antibodies have allowed identification of cells expressing
KIR2DS1, KIR2DS2, KIR3DS1, and KIR2DS5 (15, 16, 22–24, 34–
38). The possibility to identify the specific expression of distinct
aKIRs has made it possible to determine how these receptors reg-
ulate NK cell function at the single level, and in concert with other
activating and inhibitory HLA class I-binding receptors.
KIR2DL4 remains a particular KIR because of its structure,
expression, and functions (39). Hence, this receptor is expressed
by all NK cells, in contrast to other KIRs, which are clonally
expressed. KIR2DL4 has also a lower diversity but its allele diver-
sity influences the surface expression and function in NK cells
(40, 41). Hence, the 9A allele of KIR2DL4 is not stable at the
plasma membrane and is rapidly recycled. Consequently, intracel-
lular KIR2DL4, engagement with its ligand HLA-G in endocytosis
vesicles resulted in production of cytokines such as IFN-γ but
also other cytokines such as IL-1β, TNF-α, and IL-8, etc., [nicely
reviewed by Rajagopalan and Long (39)].
THE ELUSIVE NATURE OF ACTIVATING KIR LIGANDS
Despite the high degree of sequence homology between activat-
ing and inhibitory KIRs, the specificities of most aKIRs remain
elusive. In particular, this is true for KIR2DS1, KIR2DS2, and
KIR3DS1. KIR2DS1, the first described, and most well-studied
activating KIR, binds to HLA-C molecules within the C2 group
(with the N77/K80 motif) (12). KIR2DS2 has been shown to
recognize group 1 HLA-C and induce a KIR–HLA-dependent
NK cell activation (42, 43). However, many other studies have
failed to identify KIR2DS2–HLA-C1 interaction [nicely reviewed
by Moesta and Parham (44)]. Unexpectedly, a recent publication
revealed that KIR2DS2 recognizes HLA-A*11 (18). With respect
to KIR3DS1, while there are indications that KIR3DS1 interacts
with HLA-Bw480I, there have been no studies demonstrating a
direct interaction between these two molecules (24). In contrast
to the above-mentioned aKIRs, KIR2DS3 and KIR2DS5 have no
inhibitory counterparts. Although detection at the cell surface of
NK cells has been recently proven possible (19, 21), the iden-
tification of their respective ligand(s) has not been successful.
KIR2DS4 however has been shown to interact with HLA-A*11:02,
HLA-C*05:01, and HLA-C*16:01 (20).
It is possible that the aKIRs have HLA class I as their major lig-
ands. However, it also remains possible that these receptors could
recognize altered HLA class I complexes, e.g. specific HLA/peptide
complexes, or complexes of HLA class I together with viral pro-
teins, or non-HLA class I ligands altogether (45). For example,
KIR2DS4 has been suggested to bind to an unidentified pro-
tein expressed on melanoma-derived tumor cells, independently
of HLA class I (46). In mice, the activating Ly49H receptor
directly recognizes the CMV-encoded protein m157 (47, 48),
and thereby allows NK cells to control CMV infection. Simi-
larly, mouse CMV m04 together with the MHC class I molecule
H-2Dk allows recognition of CMV-infected cells by NK cells
expressing the activating receptor Ly49P (49). It thus remains pos-
sible that the aKIRs could directly, or indirectly, recognize virally
encoded ligands, although such ligands have yet to be identified in
humans.
Several iKIRs display a certain degree of peptide selectivity,
where the nature of the HLA class I presented peptide affects the
binding to KIRs (43, 45, 50, 51). Similarly, KIR2DS1 displays a
certain degree of peptide selectivity in its binding to HLA-Cw4
(43), indicating that also aKIRs can be modulated by the nature
of the presented peptide. Noteworthy the recent crystal struc-
ture of KIR2DS2–HLA-A*11:01 was obtained in complex with a
vaccinia viral peptide (18). Moreover, the authors showed that pep-
tide sequence affects the binding of KIR–HLA. Additionally, HLA
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allele themselves can display a different affinity for their attributed
KIR (42).
In addition to alterations in peptide content during, e.g., viral
infections, the overall cell surface pattern of MHC class I can be
altered. Interestingly, it was recently shown in mouse, that peptide-
specific clusters of HLA class I/peptide complexes are formed on
the cell surface of infected cells, depending on the nature of the
peptide presented (52). These peptide-specific clusters create a
high level of expression of a given MHC class I/peptide complex
on the cell surface of infected cells, which allow a more efficient
recognition by cognate T cell receptors (52). It is tempting to spec-
ulate that in humans, the clustering of specific HLA class I/peptide
complexes during infections could be one way for aKIRs to recog-
nize virus-infected cells. Noteworthy, most studies on aKIRs have
evidenced a weaker affinity for their ligands compared to their
inhibitory counterparts (43, 44).
EDUCATION OF NK CELLS BY ACTIVATING KIR
Activating KIRs convey their signals through the adaptor
KARAP/DAP12 (53, 54). Upon ligation with antibodies or lig-
ands, Src kinase-dependent phosphorylation of DAP12 allows the
recruitment of SYK and the triggering of LAT-dependent signaling
pathways (PI3K–AKT, NKFAT, and MAPK) (55).
As mentioned above, the ligands for most aKIRs remain elusive
and KIR2DS1 is the activating receptor with the best described
ligand (HLA-C2) (43, 56, 57). Several studies have shown that
KIR2DS1+ NK cells efficiently kill HLA-Cw4+ target cells (12,
14, 15, 43, 45, 58). However, it has been hard to reconcile the
fact that NK cells can express activating receptors whose ligand
is expressed on healthy cells, as this interaction potentially could
lead to autoreactivity. To cope with potential autoreactivity, it is
likely that NK cells, much like T cells, have evolved a system for
tolerance also for aKIRs. One possibility is negative selection of
NK cells expressing self-HLA class I-binding aKIRs in the absence
of self-specific inhibitory KIRs. However, recent data refuted this
hypothesis, as NK cells expressing KIR2DS1 in the absence of
self-specific inhibitory KIRs or CD94/NKG2A can be detected in
HLA-C2+ donors (15, 36, 37, 59).
An alternative hypothesis is that NK cells expressing aKIRs
are not deleted, but rather rendered hyporesponsive if the ligand
is present in the host. Indeed, in HLA-C2 homozygous donors
NK cells expressing KIR2DS1 in the absence of self-HLA class
I-specific KIRs (KIR2DS1sp) were hyporesponsive to target cell
stimulation, whereas no such hyporesponsiveness was observed in
HLA-C1 homozygous donors (15), indicating that the responsive-
ness of KIR2DS1+NK cells is tuned down in HLA-C2 homozygous
donors (15, 59). Similarly, IL-2 activated KIR2DS1sp NK cell lines
and clones from HLA-C2 homozygous donors have been reported
to have lower responses to HLA-C2+ target cells (14, 59).
This newly identified NK cell education complements edu-
cation via inhibitory HLA class I-binding receptors (iKIR and
NKG2A/CD94), since it renders otherwise potentially autoreactive
NK cells self-tolerant. The system of iKIR- and aKIR-mediated
education can in some ways be compared to the positive and
negative selection of T cells; where T cells are positively selected
based on having TCRs that recognize self-MHC class I, and neg-
atively selected if they express a TCR that recognize MHC class
I in complex with self-peptides. In comparison with the T cells,
education by iKIR would be the analog of positive selection, and
education via aKIRs would be the analog of negative selection,
with the major difference that T cell selection results in deletion or
survival, whereas for NK cells it sets the threshold for activation,
without affecting survival (60, 61).
Interestingly, although the mechanisms have not yet been
identified, education by aKIRs shares features with the hypore-
sponsiveness induced by chronic stimulation of other activating
receptors expressed by NK cells. For example, chronic exposure
to NKG2D ligands in mice renders NK cells hyporesponsive to
target cells (62). Similarly, when the ligand (m157) for the acti-
vating Ly49H is constitutively expressed, mouse Ly49H+ NK cells
become hyporesponsive (63). Finally, NK cells in NKp46-deficient
mice are more responsive, suggesting that NKp46 hampers the
reactivity of NK cells via an unidentified constitutively expressed
ligand (64). Thus, the mechanism ensuring tolerance by self-HLA
class I-binding aKIRs might be similar to that of these activating
receptors. Other examples of activating receptor-dependent NK
cell tolerance exist but the molecular mechanisms are likely to be
different. For instance, mouse 2B4 may be associated with different
adaptors that transmit inhibitory or activating signals (65). Inter-
estingly, the tuning of NK cells expressing self-HLA class I-binding
aKIRs seems to be restricted to target cell recognition, as it does
not affect the response to cytokine stimulation (15). Furthermore,
based on murine studies, education of NK cells appears to be a
dynamic and reversible process, both via activating and inhibitory
receptors (66, 67). This suggests that NK cells expressing self-HLA
class I-binding receptors may be silenced under normal condi-
tions, but once an appropriate signal is given to the cells, they
may become an important component of an efficient immune
response. For example, sudden changes, in contrast to chronic
long-term changes, might provide such a signal, a concept that was
recently proposed in the“discontinuity theory for immunity”(68).
Compiling all relevant literature, the authors noted that innate
immune cells, but also to some extent adaptive immune cells, are
tolerant to “self,” irrespective of how aberrant the “self” is, until an
“unexpected” event disrupts the equilibrium that is maintaining
tolerance, thus awakening the immune effectors.
Overall, the iKIR- and aKIR-dependent education of NK cells
by HLA class I molecules, together with the polymorphic nature
of KIRs and HLA class I, and the variegated expression of KIRs
on NK cells, results in a highly complex system of NK cell regu-
lation. The effects of this complex system are only just starting to
be investigated in different diseases, and most available data thus
comes from genetic studies.
ACTIVATING KIRs IN VIRAL INFECTIONS
Over the past 10 years, a number of studies have aimed at elu-
cidating a potential role of aKIRs in virus infections, including
HIV, HCV, and CMV. There is now compelling evidence, although
mostly at the genetic level, that aKIRs can affect the outcome of
different infections. The large degree of linkage disequilibrium
between different KIR genes, e.g., KIR2DL2 and KIR2DS2, and
KIR2DS1 and KIR3DS1, however makes it hard to pinpoint a spe-
cific KIR/HLA class I interaction at the genetic level, as responsible
for protection or susceptibility to a given infection. In addition,
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the lack of well-characterized ligands for several of the aKIRs, e.g.,
KIR3DS1, KIR2DS2, and KIR2DS3, as well as the lack of specific
monoclonal antibodies to these aKIRs have severely hampered
investigations of the functional role of these receptors in viral
infections. The identification of ligands and the development of
new antibodies specific for aKIRs are thus required to move the
field forward toward understanding how these receptors regulate
NK cell function in different infectious disease settings.
KIR3DS1 is the by far most well-studied aKIR in the setting
of infectious diseases [also nicely reviewed by Körner and Altfeld
(69)]. The first evidence for a role of KIR3DS1 in viral infections
came from genetic studies in HIV-infected individuals where indi-
viduals homozygous for KIR3DS1 progressed slower to AIDS, but
only if they also carried HLA-Bw4 with an isoleucine at posi-
tion 80 (HLA-Bw480I) (70). Interestingly, donors homozygous for
KIR3DS1, but lacking HLA-Bw480I progressed faster to AIDS (70).
Furthermore, HLA-Bw480I+ individuals with increasing number
of copies of KIR3DS1 due to copy number variation have been
shown to have lower viral load set points (71). The frequency of
KIR3DS1 positive individuals has also been shown to be higher in
HIV-exposed seronegative individuals, compared to HIV seroposi-
tive and HIV negative individuals, indicating that KIR3DS1 might
also be providing protection against infection (72). In addition,
the frequency of KIR3DS1+KIR3DL1− NK cells is increased in
HLA-Bw480I+ individuals, both at acute and chronic stages of
HIV infection compared to healthy controls (73). The protec-
tive effect of KIR3DS1 in HIV infection was further strengthened
by evidence that individuals carrying both KIR3DS1 and HLA-
Bw480I suppress HIV replication in vitro to a greater extent than
NK cells from individuals carrying KIR3DS1 in the absence of
HLA-Bw480I, or vice versa, carrying HLA-Bw480I in the absence
of KIR3DS1 (56). In addition, purified KIR3DS1+KIR3DL1− NK
cells from HLA-Bw480I+ individuals suppressed HIV replication
in vitro to a much greater extent than KIR3DS1−KIR3DL1+ and
KIR3DS1−KIR3DL1− NK cells (56), indicating that the effect of
KIR3DS1 is likely to be mediated by KIR3DS1+ NK cells, and
not by KIR3DS1+ T cells. The same group subsequently demon-
strated that the effect of KIR3DS1 on viral inhibition in vitro
was highest in individuals carrying KIR3DS1, HLA-Bw480I, and
at least one copy of KIR3DL1 (71). Surprisingly, NK cells from
HLA-Bw480I+ individuals homozygous for KIR3DS1, but lack-
ing KIR3DL1, did not suppress HIV replication in vitro to a
greater extent than NK cells from HLA-Bw6 homozygous indi-
viduals, indicating that the effect of KIR3DS1 is dependent on
both KIR3DL1 and HLA-Bw480I. Interestingly, the expression of
KIR3DS1, both at the mRNA and protein level, was elevated
in individuals carrying KIR3DS1 in the presence of two copies
of KIR3DL1, compared to individuals carrying KIR3DS1 in the
presence of one copy of KIR3DL1. However, that study did not
compare the expression levels of KIR3DS1 to individuals carry-
ing two copies of KIR3DS1 in the absence of KIR3DL1, making it
hard to determine whether increased expression levels of KIR3DS1
alone could explain the increase in viral inhibition, as suggested
by the authors. An alternative explanation for the increased sup-
pression of HIV replication by KIR3DS1/KIR3DL1 heterozygous
individuals, compared to KIR3DS1 homozygous individuals could
be an increased efficiency of NK cells co-expressing KIR3DL1 and
KIR3DS1, potentially allowing NK cells to sense a down regulation
of HLA-Bw4 via KIR3DL1, and at the same time activate them via
KIR3DS1-mediated recognition of HLA-Bw4 with, e.g., an altered
peptide repertoire. However, sorted KIR3DL1+ NK cells from
KIR3DS1/KIR3DL1 heterozygous individuals, that could contain
NK cells co-expressing KIR3DL1 and KIR3DS1, did not efficiently
suppress HIV replication in vitro, compared to NK cells expressing
only KIR3DS1 (56). This indicates that co-expression of KIR3DL1
and KIR3DS1 is not required for KIR3DS1-mediated NK cell sup-
pression of HIV replication in vitro. It is also noteworthy that
very little is known about co-expression of other activating and
inhibitory KIRs and other HLA class I-binding receptors (e.g.,
NKG2A, NKG2C, and LIR-1) on KIR3DS1+ NK cells, both in
healthy and in HIV-infected individuals.
The complexity of the effects of KIR3DS1 in HIV infection is
further highlighted by reports that KIR3DS1 is associated with an
increased progression to AIDS, but when restricted to HLA-Bw4+
individuals, KIR3DS1 presence is associated with a slower progres-
sion (74). Other reports have suggested an HLA-Bw4-independent
effect of KIR3DS1 in HIV-infected individuals, at least when mea-
suring CD8 T cell activation, which is strongly associated with
HIV disease progression (75). Taken together, the data collected
to date indicate a role for KIR3DS1 in HIV disease and progres-
sion to AIDS, but it is also clear that more efforts are needed to
explain the complex nature of KIR3DS1-mediated protection in
HIV-infected individuals, including the identification of a ligand
for this receptor.
In contrast to the role of KIR3DS1 in HIV infection, much less is
known about the role of other aKIRs in viral infections. Similar to
studies of aKIR and HIV, most of the studies have been performed
at the genetic level, and commonly in smaller cohorts of patients.
Nevertheless, a number of studies have implicated a role for aKIRs
in other viral infections. For example, the frequency of KIR2DS3
positive individuals is higher in patients with chronic HCV infec-
tion, compared to individuals that have resolved HCV infection
(76). Interestingly, the detrimental effect of KIR2DS3 was only
observed in HLA-C2+ individuals, which is not believed to be a lig-
and for KIR2DS3 (76). An increase in KIR2DS3, as well as KIR2DS2
positive individuals has also been reported in a Brazilian cohort of
chronically HCV-infected patients (77). Whether the association
between KIR2DS3 and chronic HCV infection reflects a direct
interaction between HCV-infected cells and KIR2DS3+ NK cell
remains unknown since there is neither a known ligand, nor spe-
cific antibodies for KIR2DS3. A likely explanation proposed by
Dring et al. is that KIR2DS3 is instead a marker of a particular
haplotype that is associated with the disease progression (76).
In addition to a role for KIR3DS1 in HIV infection, KIR2DS2
has been associated with faster progression to AIDS (74). A similar
association was found in a West African cohort of HIV-infected
women, where haplotype B KIRs, including KIR2DS2, KIR2DS3,
and KIR3DS1, was associated with lower CD4 T cell counts (78).
Interestingly, homozygosity for HLA-C1, a putative ligand for
KIR2DS2 and KIR2DS3, decreased the association between lower
CD4 T cell counts and the aKIRs. However, there is no evidence
for a direct functional role of KIR2DS2 or KIR2DS3 in recogni-
tion of HIV-infected cells. Because HLA-C is not downregulated
by HIV-infected cells (79), it is tempting to speculate that NK
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cells expressing HLA-C-binding aKIRs in the absence of HLA-C-
binding iKIRs, could mediate recognition of HIV-infected cells.
For example, KIR2DS1+KIR2DL1− NK cells, which are activated
by interaction with HLA-C2+ target cells, could potentially rec-
ognize HIV-infected cells in HLA-C2+ individuals. The lack of
effects of KIR2DS1/HLA-C2 in HIV infection could potentially be
explained by the education of NK cells via aKIRs,where KIR2DS1+
NK cells in HLA-C2+ individuals are hyporesponsive.
In addition to the associations between activating KIRs and
viral infections described above, KIR2DS1 and KIR2DS3 have also
been associated with fatal outcome in Ebola infection. The fre-
quencies carriers of both these genes were increased in patient
cohorts with fatal outcome of Ebola infections, compared to sur-
vivors, contacts, and healthy controls (80). However, as the study
investigated a rather small cohort, no further dissection of interac-
tions between these aKIRs and HLA-C was possible. Expansions of
KIR2DS2+, KIR2DS4+, and KIR3DS1+ NK cells have also been
reported to occur in a subset of CMV seropositive individuals
(17). However, direct evidence for a role of these aKIRs in the
recognition of CMV-infected cells is still lacking.
In summary, although there are a fairly large number of stud-
ies associating KIR gene content with outcome of viral infections,
more direct functional evidence for a role of aKIRs in recognition
of virus-infected cells is lacking. The identification of novel, possi-
bly virus-encoded or virus-induced, ligands for activating KIRs, as
well as specific monoclonal antibodies, are required to understand
the role of these receptors in viral infections.
ACTIVATING KIR IN CANCER
A number of studies have investigated the associations between
inhibitory and activating KIR and cancer prognosis. However, sim-
ilar to the role of aKIRs in infections, the evidence for a role for
aKIRs in cancer has largely been at the genetic level due to the
limitations in available specific monoclonal antibodies. The edu-
cation of NK cells via aKIR/HLA class I may play a significant role
in controlling NK cell responses to transformed cells, as NK cells
expressing aKIRs are hyporesponsive in the presence of self-HLA
class I ligands. NK cells expressing aKIR in individuals where the
ligand is present will be hyporesponsive, and thus may not be able
to mount an efficient response against tumor cells in the same
individual. Conversely, NK cells expressing aKIRs in individuals
where the ligand is not expressed will not be able to recognize the
tumor cells due to the lack of the ligand. However, it remains pos-
sible that there are hitherto unknown ligands for aKIRs expressed
on tumor cells (46), potentially providing a role for aKIRs in
various cancers. A recent study evidenced that CCR7 expressed
by dendritic cells or lymphoblasts could be transferred to NK
cells in a KIR2DS1/HLA-C2-dependent manner. Consequently,
CCR7+ NK cells would migrate to secondary lymphoid organs
and further improve anti-leukemic effect of NK cells, notably after
hematopoietic stem cell transplantation (haplo-HSCT) (81).
The role of activating KIRs in cancer seems to vary with type of
cancer, therapy and clinical measurement, and evidence for both
protective and detrimental effects exist. For example, KIR2DS1
gene frequency was found to be higher in breast cancer patients
compared to healthy controls, and in contrast to KIR2DL1 was sug-
gested to promote cancer progression (82). Similarly, individuals
with chronic myeloid leukemia carrying the KIR2DS1 gene had a
lower response to antibody-treatment with Imatinib (Glivec) (83).
In addition, multiple myeloma patients carrying KIR3DS1 had
shorter progression-free survival (PFS), compared to those that
lacked KIR3DS1, after autologous stem cell transplantation (84).
However, among the KIR3DS1 positive individuals in that study,
patients carrying HLA-Bw4 had longer PFS compared to those
lacking HLA-Bw4. In contrast, Karabon et al. recently reported that
KIR3DS1 positive individuals with B cell lymphocytic leukemia
(B-CLL) had a trend toward longer progression-free survival com-
pared to KIR3DS1 negative individuals. Interestingly however,
in the same study co-carriage of KIR3DS1 among HLA-Bw4+
patients, as well as co-carriage of KIR2DS1 in HLA-C2+ patients
were associated with longer PFS (85).
Allogeneic stem cell transplantation to treat leukemia is one set-
ting where NK cells expressing aKIRs may play a significant role,
in particular when using KIR ligand mismatched donor/recipient
pairs. In this setting, aKIR+ NK cells from donors lacking expres-
sion of ligands for the aKIRs could potentially recognize the
recipients’ leukemia blasts, e.g., when transplanting a HLA-C2
positive recipient with cells from a KIR2DS1 positive but HLA-
C2 negative donor. Indeed, it was recently shown in acute myeloid
leukemia that patients receiving allografts from KIR2DS1 positive
donors had a lower probability of relapse, but only if the donor
was not homozygous for HLA-C2 (86). Interestingly, there was
no difference in relapse between HLA-C2 homozygous patients
receiving a KIR2DS1 positive allograft, compared to those receiv-
ing a KIR2DS1 negative allograft. In contrast, there was a lower
probability of relapse in HLA-C1/C1 and HLA-C1/C2 patients
receiving a KIR2DS1 positive allograft, compared to those receiv-
ing a KIR2DS1 negative allograft (86). Based on their data, the
authors concluded that it would be beneficial to select KIR2DS1
positive HLA-C1 positive donors for transplantation into HLA-
C1 positive donors, and suggested that tolerance-induction via
KIR2DS1/HLA-C2 could potentially explain the lack of effects
when the allograft was derived from KIR2DS1 positive HLA-
C2/C2 donors. The data are also compatible with KIR2DS1+
donor NK cell education via interactions with HLA-C2 in the
recipient, since there was no effect of donor KIR2DS1 in HLA-
C2/C2 recipients. However, it is hard to reconcile how KIR2DS1+
NK cells could mediate an anti-leukemic effect when transplanted
into HLA-C1 positive donors, as there would be no ligand for
KIR2DS1 expressed by the recipient’s leukemia blasts. One pos-
sible explanation, which is still compatible with aKIR-mediated
education, is that an unknown non-HLA class I ligand is expressed
by leukemic blasts, and as such provides a mechanism by which
KIR2DS1+ NK cells could recognize the leukemia blasts, but only
if the donor-derived KIR2DS1+ NK cells are not rendered toler-
ant by the donors or recipient’s HLA-C2. However, no such ligands
been identified to date. In addition to the study by Venstrom et al.
(86), several other studies have indirectly indicated an effect of
activating KIR in hematopoietic cell transplantation. In a study
with over 1000 AML patients, receiving grafts from KIR haplo-
type B donors, in particular KIR cen-B homozygous donors, was
associated with a higher relapse-free survival, compared to those
receiving grafts from KIR haplotype A/A donors, which lack most
aKIRs (87, 88). Interestingly, no effect of donor KIR haplotype B
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was observed on outcome of ALL in the same study. In contrast
to these studies, McQueen et al. reported that KIR haplotype A/A
patients with AML/MDS receiving KIR haplotype B grafts (con-
taining aKIR) had a lower survival together with a higher relapse
and GvHD rates, compared to KIR haplotype A/A donors receiving
a KIR haplotype A/A graft (89). It should however be noted that
the number of patients with KIR haplotype A/A receiving a KIR
haplotype B graft in that study was low (8–11 patients), making it
hard to draw firm conclusions.
More direct evidence for a role of aKIRs in tumor recog-
nition was provided by Pende et al. in patients receiving hap-
loidentical haplo-HSCT from KIR ligand-mismatched donors.
Donor-derived KIR2DS1+ NK cells were shown to efficiently kill
HLA-C2+ leukemia blasts, indicating that aKIRs could mediate
important anti-leukemic effects in the setting of bone marrow
transplantation (90).
Overall, although a number of studies have analyzed the co-
carriage of KIR genes and their ligands, general conclusions
regarding the role of aKIR in cancer and cancer therapy cannot
be drawn, as it is likely that the role of aKIRs will vary depending
on the type of cancer and treatment. Given the linkage disequilib-
rium of activating KIRs, large cohorts of well-defined patients are
needed to pinpoint the role of specific aKIRs, as well as the pres-
ence of their ligands. In addition, functional data investigating the
role of aKIRs, and education via these receptors, is largely lacking.
More studies monitoring aKIR-dependent NK cell functions are
thus warranted in order to decipher the impact of aKIR-mediated
education on cancer incidence and progression.
ACTIVATING KIR IN HUMAN REPRODUCTION
More and more studies reveal the presence of NK cells in tissue
and in particular uterine NK (uNK) cells have been found highly
interesting with regard to their regulation by aKIRs. uNK cells
represent the dominant leukocyte subset in the decidua (uterine
endometrium in pregnancy) during the initial period of pregnancy
(91). The uNK cells have been linked to the particular physiologi-
cal changes that the implantation of the embryo to the uterine wall
entails [elegantly reviewed by Mofett and Loke (92)]. Briefly, dur-
ing the initial stages of pregnancy, fetal extravillous trophoblasts
(EVT) implant the embryo by invading into the maternal uter-
ine wall and remodel uterine spiral arteries to ensure the supply
of oxygen and nutrients to the growing placenta and fetus. EVTs
are peculiar in that they express no HLA-A and -B, but do express
HLA-C, -E, and -G. Interestingly, KIR2DL1/S1 and KIR2DL2/3/S2
expression is more frequent on uNK cells than on matched periph-
eral blood NK cells (93), suggesting a tissue-specific role for KIRs
on the uNK cells (which also express KIR2DL4, NKG2A, and
LILRB1). The invading EVT reside in the same anatomical loca-
tion as uNK cells and it has been hypothesized that KIR/KIR ligand
combinations thus affect implantation and pregnancy success.
In support of this, mothers lacking activating KIR genes (hap-
lotype A/A), who consequently express only inhibitory KIR2DL1,
in combination with a HLA-C2+ fetus, were at higher risk for
preeclampsia and IUGR (94). In contrast, presence of the activat-
ing KIR2DS1 gene was protective, which indicated that activation
of uNK cells via aKIR might be important in the interaction with
EVT. Indeed, the same group recently showed that KIR2DS1 is
functional on uNK cells (95). KIR2DS1 had an educating effect
on uNK cells in HLA-C2 donors with regard to target cell induced
degranulation, similar to the effect described for peripheral blood
NK cells (15). However, signaling via KIR2DS1 on uNK cells also
led to production of GM-CSF that could be used to attract tro-
phoblasts in vitro. Together this provides mechanistic insight into
the in vivo importance for activating KIR on uNK cells, in their
potential interaction with EVT. Regarding other aKIRs on uNK
cells, KIR2DS4 is also expressed on uNK cells, and using clonally
expanded uNK cells, KIR2DS4 has been shown also to be func-
tional (96). Future experiments will reveal whether KIR2DS4 plays
a similar role as KIR2DS1 in the regulation of uNK cell function.
HLA-G is expressed by trophoblasts and KIR2DL4 is also expressed
by uNK cells. Expression of soluble HLA-G during pregnancy has
been documented (92) and correlates with successful pregnancy
(97). Consequently, intracellular KIR2DL4, engagement with its
ligand HLA-G in endocytosis vesicles would result in produc-
tion of various cytokines, which may have vascular remodeling
consequences similar to KIR2DS1 activation (98).
ACTIVATING KIR IN AUTOIMMUNE OF INFLAMMATORY
DISEASE
The relationships between KIR expression and autoimmune or
inflammatory disorders remain largely unknown. Similarly to
other diseases, the role of interaction between aKIRs and HLA class
I has only been extrapolated from genetic studies looking both at
KIR and HLA gene expression. KIR2DS1 gene was suggested to
be less common in patients with atopic dermatitis compared to
healthy controls (99), suggesting that that KIR2DS1 might have a
protective effect. In contrast, KIR2DS1 was found more often in
patients with systemic lupus erythematous (100), and the same
was true for KIR3DS1 in multiple sclerosis (MS) (101). Psoria-
sis vulgaris is also characterized by a clear association between
KIR2DS1 and HLA-Cw6, whose co-carriage was over-represented
in patients (102, 103). In this setting, Łuszczek et al. hypothe-
sized that interactions between KIR2DS1 and its ligand would
contribute to pathogenesis. Given that KIR2DS1+ NK cells are
normally hyporesponsive in HLA-C2 positive donors, these stud-
ies indicate that there is a potential break of tolerance leading to
psoriatic lesions. In contrast, a former study on psoriatic arthritis
showed that KIR2DS1 and KIR2DS2 were associated with suscep-
tibility to disease, but only in the absence of their cognate HLA
ligands (104). Although responsiveness of KIR2DS1+ NK cells
must be assessed, it is possible that an aKIRs education-dependent
higher responsiveness would render KIR2DS1+ NK cells able to
mediate autoimmune reactions, in the absence of HLA-C2, thus
recognizing an unknown ligand.
CONCLUDING REMARKS
Although significant progress has been made in the understand-
ing of aKIRs and their interactions with HLA class I, the role of
aKIRs in disease and health still remains largely unexplored. The
studies of aKIR/HLA class I associations indicate that aKIRs are
likely to play a role in a number of different diseases, including
infectious diseases, cancer, and autoimmunity. However, the lack
of specific monoclonal antibodies to analyze expression patterns
of aKIRs, together with their polymorphic nature and linkage
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disequilibrium with iKIRs have hampered detailed studies of
aKIRs both in disease and in health. The development of spe-
cific antibodies, as well as the identification of ligands for aKIRs,
potentially including non-HLA class I molecules, would greatly
advance our understanding of aKIR biology. Finally, it is impor-
tant to keep in mind that KIR expression is not restricted to NK
cells but expression has also been documented on αβ and γδT cells
(105, 106). Particularly forαβT cells and infection or autoimmune
diseases where polymorphism of HLA is important, the expression
of aKIR might shed light on these genetic associations.
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